140 related articles for article (PubMed ID: 27930645)
1. When to initiate treatment in myelofibrosis.
Harrison C
Clin Adv Hematol Oncol; 2016 Nov; 14(11):934-937. PubMed ID: 27930645
[No Abstract] [Full Text] [Related]
2. Recent advances in the management of myelofibrosis.
Mesa RA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):597-9. PubMed ID: 27487103
[No Abstract] [Full Text] [Related]
3. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.
Li B; Zhang P; Feng G; Xu Z; Qin T; Zhang Y; Sha Z; Dong D; Zhang H; Fang L; Pan L; Hu N; Qu S; Cai W; Huang G; Xiao Z
Blood Cancer J; 2016 Dec; 6(12):e505. PubMed ID: 27935577
[No Abstract] [Full Text] [Related]
4. Myelofibrosis: clinicopathologic features, prognosis, and management.
O'Sullivan JM; Harrison CN
Clin Adv Hematol Oncol; 2018 Feb; 16(2):121-131. PubMed ID: 29741513
[TBL] [Abstract][Full Text] [Related]
5. [Pathophysiology of and therapy for primary myelofibrosis].
Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1724-32. PubMed ID: 17802728
[No Abstract] [Full Text] [Related]
6. Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
Passamonti F
Leuk Res; 2014 Mar; 38(3):290-1. PubMed ID: 24444869
[No Abstract] [Full Text] [Related]
7. [Current views on the pathogenesis and treatment of spontaneous (primary) myelofibrosis].
Robak T
Pol Tyg Lek; 1992 Feb 3-10; 47(5-6):144-7. PubMed ID: 1437804
[No Abstract] [Full Text] [Related]
8. Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy.
Siebolts U; Lange T; Niederwieser D; Wickenhauser C
J Clin Pathol; 2010 Apr; 63(4):370-2. PubMed ID: 20354212
[TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
10. Reduced intensity transplantation: where are we now?
Mackinnon S; Thomson K; Morris E; Kottaridis PD; Peggs KS
Hematol J; 2004; 5 Suppl 3():S34-8. PubMed ID: 15190275
[No Abstract] [Full Text] [Related]
11. Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon.
Hebballi S; Akiki S; Bareford D
J Clin Pathol; 2012 Aug; 65(8):762-3. PubMed ID: 22412053
[No Abstract] [Full Text] [Related]
12. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
[No Abstract] [Full Text] [Related]
13. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B; Schaefer JK; Mercer J; Talpaz M
Blood Rev; 2021 Jan; 45():100691. PubMed ID: 32354563
[TBL] [Abstract][Full Text] [Related]
14. [Myelofibrosis in a new light. New classification introduced, new therapeutic principles on their way].
Merup M; Palmblad J
Lakartidningen; 2009 Dec 2-8; 106(49):3342, 3344-6. PubMed ID: 20104733
[No Abstract] [Full Text] [Related]
15. Personalized treatment for patients with myelofibrosis.
Kadia TM
Clin Adv Hematol Oncol; 2016 Jun; 14(6):400-3. PubMed ID: 27379807
[No Abstract] [Full Text] [Related]
16. Genetic predictors of response to specific drugs in primary myelofibrosis.
Penna D; Szuber N; Lasho TL; Finke CM; Vallapureddy RR; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2018 Nov; 8(12):120. PubMed ID: 30455475
[No Abstract] [Full Text] [Related]
17. Education and Imaging. Hepatobiliary and Pancreatic: A rare cause of portal hypertension.
Plaz Torres MC; Romana C; Coppo C; Zentilin P; Grillo F; Savarino V; Giannini EG
J Gastroenterol Hepatol; 2016 Jan; 31(1):11. PubMed ID: 26177884
[No Abstract] [Full Text] [Related]
18. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
19. [Idiopathic myelofibrosis in internal medicine].
García-Gutiérrez V; Redondo S; Ruedas A
Med Clin (Barc); 2014 Dec; 143(11):498-501. PubMed ID: 25088655
[No Abstract] [Full Text] [Related]
20. Choosing between stem cell therapy and drugs in myelofibrosis.
Kröger N; Mesa RA
Leukemia; 2008 Mar; 22(3):474-86. PubMed ID: 18185525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
